US plans to administer 20 million COVID-19 vaccine doses by December

Spread the love

Several countries in different parts of the globe are observing a spike in their daily Covid-19 cases and deaths. Alongside, various cities like New York in United States, Turin in Italy and London in the UK have been placed under strict lockdown with the rising probability of being hit by a second wave of Covid-19 outbreak.

Whilst stringent lockdown has been implemented, the governments have also enhanced the testing counts and surveillance for identifying largely those infected with the virus as soon as possible for helping to prevent the contagion of the disease.

The AFP agency reported that an expert from World Health Organization that the distrust of public would render the best treatments ineffective against the Covid-19 pandemic.

The United States anticipates to administer 20 million vaccine doses to the citizens in December and at least a count of 25 million per months in the upcoming year. The chief adviser of Operation Warp, Moncef Slaoui, declared about it in a press event, anticipating that Pfizer and Moderna, having vaccines in clinical trials, might take the leap of approving it for emergency use.

A Hyderabad based biopharmaceutical, will commence the clinical trial of vaccine candidate Biological E at the All India Institute of Medical Sciences (AIIMS), Patna from Monday, with volunteers participating from 18 – 55 age group.

Who in alliance with Gavi have developed COVAX will be focused on providing access to the Covid-19 vaccine candidate, and has surpassed the target of hailing over $2 billion for buying and distributing vaccine to poorer countries.

South Korea’s Ralpha will be manufacturing 150 million doses of Sputnik V annually as announced by Russian Direct Investment Fund (RDIF)

SII might get the authority by December when the final stage trial of AstraZeneca’s vaccine provides effective results, as reported by Bloomberg.

Leave a Reply

Your email address will not be published. Required fields are marked *

error: Content is protected !!